Your browser doesn't support javascript.
loading
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Cohen, Adam D; Mateos, María-Victoria; Cohen, Yael C; Rodriguez-Otero, Paula; Paiva, Bruno; van de Donk, Niels W C J; Martin, Thomas; Suvannasankha, Attaya; De Braganca, Kevin C; Corsale, Christina; Schecter, Jordan M; Varsos, Helen; Deraedt, William; Wang, Liwei; Vogel, Martin; Roccia, Tito; Xu, Xiaoying; Mistry, Pankaj; Zudaire, Enrique; Akram, Muhammad; Nesheiwat, Tonia; Pacaud, Lida; Avivi, Irit; San-Miguel, Jesus.
Afiliação
  • Cohen AD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Mateos MV; Hospital Clinico Universitario de Salamanca, Salamanca, Spain.
  • Cohen YC; Tel-Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Rodriguez-Otero P; Clinica Universidad de Navarra, CCUN, Centro de Investigación, Medica Aplicada (CIMA), Instituto de Investigación, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16/12/00369, Pamplona, Spain.
  • Paiva B; Clinica Universidad de Navarra, CCUN, Centro de Investigación, Medica Aplicada (CIMA), Instituto de Investigación, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16/12/00369, Pamplona, Spain.
  • van de Donk NWCJ; Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Martin T; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Suvannasankha A; Indiana University Simon Cancer Center, Indiana University and Roudebush VAMC, Indianapolis, IN.
  • De Braganca KC; Janssen R&D, Raritan, NJ.
  • Corsale C; Janssen R&D, Raritan, NJ.
  • Schecter JM; Janssen R&D, Raritan, NJ.
  • Varsos H; Janssen R&D, Raritan, NJ.
  • Deraedt W; Janssen R&D, Beerse, Belgium.
  • Wang L; Janssen R&D, Raritan, NJ.
  • Vogel M; Janssen Global Services, LLC, Raritan, NJ.
  • Roccia T; Janssen Global Services, LLC, Raritan, NJ.
  • Xu X; Janssen R&D, Raritan, NJ.
  • Mistry P; Janssen R&D, High Wycombe, United Kingdom.
  • Zudaire E; Janssen R&D, Springhouse, PA.
  • Akram M; Legend Biotech USA Inc., Piscataway, NJ.
  • Nesheiwat T; Legend Biotech USA Inc., Piscataway, NJ.
  • Pacaud L; Legend Biotech USA Inc., Piscataway, NJ.
  • Avivi I; Tel-Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • San-Miguel J; Clinica Universidad de Navarra, CCUN, Centro de Investigación, Medica Aplicada (CIMA), Instituto de Investigación, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16/12/00369, Pamplona, Spain.
Blood ; 141(3): 219-230, 2023 01 19.
Article em En | MEDLINE | ID: mdl-36095849
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Neurotóxicas / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Neurotóxicas / Receptores de Antígenos Quiméricos / Mieloma Múltiplo Idioma: En Ano de publicação: 2023 Tipo de documento: Article